Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide.
Outstanding track record and undervalued.
Share Price & News
How has Biogen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDP has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IDP exceeded the German Biotechs industry which returned 9.4% over the past year.
Return vs Market: IDP exceeded the German Market which returned 0.5% over the past year.
Price Volatility Vs. Market
How volatile is Biogen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biogen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IDP (€268.45) is trading below our estimate of fair value (€389.15)
Significantly Below Fair Value: IDP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IDP is good value based on its PE Ratio (9.3x) compared to the Biotechs industry average (33.7x).
PE vs Market: IDP is good value based on its PE Ratio (9.3x) compared to the German market (19.5x).
Price to Earnings Growth Ratio
PEG Ratio: IDP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: IDP is good value based on its PB Ratio (4x) compared to the DE Biotechs industry average (5.1x).
How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDP's earnings are forecast to decline over the next 3 years (-1.4% per year).
Earnings vs Market: IDP's earnings are forecast to decline over the next 3 years (-1.4% per year).
High Growth Earnings: IDP's earnings are forecast to decline over the next 3 years.
Revenue vs Market: IDP's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: IDP's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDP's Return on Equity is forecast to be high in 3 years time (23.8%)
How has Biogen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDP has high quality earnings.
Growing Profit Margin: IDP's current net profit margins (40.8%) are higher than last year (33.8%).
Past Earnings Growth Analysis
Earnings Trend: IDP's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: IDP's earnings growth over the past year (25.8%) exceeds its 5-year average (10.1% per year).
Earnings vs Industry: IDP earnings growth over the past year (25.8%) exceeded the Biotechs industry 17.1%.
Return on Equity
High ROE: IDP's Return on Equity (46.8%) is considered outstanding.
How is Biogen's financial position?
Financial Position Analysis
Short Term Liabilities: IDP's short term assets ($8.0B) exceed its short term liabilities ($4.6B).
Long Term Liabilities: IDP's short term assets ($8.0B) do not cover its long term liabilities ($8.9B).
Debt to Equity History and Analysis
Debt Level: IDP's debt to equity ratio (47%) is considered high.
Reducing Debt: IDP's debt to equity ratio has increased from 5% to 47% over the past 5 years.
Debt Coverage: IDP's debt is well covered by operating cash flow (120.4%).
Interest Coverage: IDP's interest payments on its debt are well covered by EBIT (106.7x coverage).
What is Biogen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDP's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michel Vounatsos (57yo)
Mr. Michel Vounatsos serves as Director at PerkinElmer, Inc. since March 1, 2020. He has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial ...
CEO Compensation Analysis
Compensation vs Market: Michel's total compensation ($USD18.16M) is above average for companies of similar size in the German market ($USD4.95M).
Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.
|CEO & Director||3.42yrs||US$18.16m||0.019% $8.6m|
|Executive VP & CFO||2.5yrs||US$5.81m||0.0019% $840.5k|
|Executive VP||3.25yrs||US$5.46m||0.022% $9.9m|
|Executive VP of Research & Development||8.33yrs||US$5.31m||0.0089% $3.9m|
|Executive VP & Head of Global Product Strategy and Commercialization||2.58yrs||US$4.69m||0.0024% $1.0m|
|VP & Chief Accounting Officer||1.58yrs||no data||0.00014% $61.6k|
|Senior VP & Chief Information Officer||2.5yrs||no data||no data|
|VP of Finance and Head of Investor Relations||no data||no data||no data|
|Chief Corporate & Compliance Counsel and Assistant Secretary||no data||no data||no data|
|Executive VP & Chief Human Resources Officer||2.92yrs||no data||0.0028% $1.2m|
Experienced Management: IDP's management team is considered experienced (2.8 years average tenure).
|CEO & Director||3.42yrs||US$18.16m||0.019% $8.6m|
|Independent Director||10.42yrs||US$416.64k||0.012% $5.1m|
|Independent Chairman of the Board||6yrs||US$725.31k||0.019% $8.5m|
|Independent Director||22.75yrs||US$497.10k||0.011% $5.0m|
|Independent Director||25.08yrs||US$424.39k||0.0067% $3.0m|
|Independent Director||11.92yrs||US$444.64k||0.0036% $1.6m|
|Independent Director||12.42yrs||US$421.33k||0.0067% $3.0m|
|Independent Director||10.25yrs||US$411.14k||0.0092% $4.1m|
|Independent Director||11yrs||US$422.64k||0.0067% $2.9m|
|Independent Director||11yrs||US$401.39k||0.0067% $2.9m|
Experienced Board: IDP's board of directors are seasoned and experienced ( 11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biogen Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biogen Inc.
- Ticker: IDP
- Exchange: XTRA
- Founded: 1978
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$49.423b
- Listing Market Cap: US$44.006b
- Shares outstanding: 163.19m
- Website: https://www.biogen.com
Number of Employees
- Biogen Inc.
- 225 Binney Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIIB||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 1991|
|IDP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 1991|
|IDP||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Sep 1991|
|BIIB||SNSE (Santiago Stock Exchange)||Yes||Common Stock||CL||USD||Sep 1991|
|BIIB *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Sep 1991|
|BIIB||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Sep 1991|
|BIIB-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Sep 1991|
|BIIB||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Sep 1991|
|BIIB34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1/6 COM USD0.0005||BR||BRL||Apr 2016|
|BIIB||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 13 REP 1 COM USD0.0005||AR||ARS||Apr 2019|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 22:02|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.